Eledon reports Q2 2026 results, confirms Phase 3 kidney transplant trial on track for late 2026

Eledon Pharmaceuticals said it completed a successful End-of-Phase 2 meeting with the FDA, establishing the regulatory framework for the planned Phase 3 trial of tegoprubart in kidney transplantation.¹ The company said the global trial remains on track to start in late 2026 and is expected to enroll approximately 600 patients, comparing tegoprubart to tacrolimus for non-inferiority at 52 weeks using a combined measure of biopsy-proven acute rejection, graft loss and death.¹

At the American Transplant Congress in June 2026, Eledon presented long-term Phase 2 BESTOW data. The company reported that by 18 months, kidney function measured by eGFR was significantly higher in the tegoprubart group than the tacrolimus group, with a gap of about 12 mL/min/1.73 m² (roughly 74 versus 61).¹ It also said no biopsy-proven acute rejection occurred in tegoprubart patients after the first six months, versus seven such events, or 9.4%, in the tacrolimus arm.¹

In islet cell transplantation, updated data from a University of Chicago Medicine study presented at ADA 2026 showed that all 12 type 1 diabetes patients reached insulin independence with HbA1c under 6.5%, averaging about 5.4% most recently, and no severe hypoglycemic episodes after transplant.¹

Eledon also partnered with Natera to use its Prospera kidney transplant test as the sole donor-derived cell-free DNA monitoring assay in the planned Phase 3 trial.¹

On finances, cash, cash equivalents and short-term investments totaled $88.8 million as of June 30, 2026, down from $133.3 million at year-end 2025, which the company said should fund operations into the second quarter of 2027.¹